Inspire Investing LLC Invests $1.63 Million in LivaNova PLC $LIVN

Inspire Investing LLC purchased a new position in shares of LivaNova PLC (NASDAQ:LIVN) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 25,597 shares of the company’s stock, valued at approximately $1,627,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Hantz Financial Services Inc. raised its holdings in LivaNova by 159.9% during the fourth quarter. Hantz Financial Services Inc. now owns 434 shares of the company’s stock worth $27,000 after purchasing an additional 267 shares in the last quarter. State of Wyoming acquired a new stake in shares of LivaNova in the 2nd quarter valued at approximately $31,000. EverSource Wealth Advisors LLC boosted its stake in shares of LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock valued at $32,000 after buying an additional 639 shares in the last quarter. Quarry LP acquired a new position in LivaNova during the third quarter worth $36,000. Finally, Covestor Ltd raised its position in LivaNova by 108.6% in the fourth quarter. Covestor Ltd now owns 753 shares of the company’s stock worth $46,000 after acquiring an additional 392 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on LIVN. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Robert W. Baird reduced their price target on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Mizuho boosted their price target on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. KeyCorp upped their price target on LivaNova from $83.00 to $92.00 and gave the stock an “overweight” rating in a report on Monday, June 22nd. Finally, Barclays raised their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Six investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $80.75.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the transaction, the director directly owned 7,228 shares in the company, valued at $547,521. This represents a 19.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.35% of the company’s stock.

LivaNova Trading Down 1.0%

Shares of LIVN opened at $82.24 on Wednesday. The stock has a fifty day moving average of $72.87 and a two-hundred day moving average of $67.23. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.11 and a current ratio of 1.33. The company has a market capitalization of $4.52 billion, a PE ratio of 42.18 and a beta of 0.88. LivaNova PLC has a fifty-two week low of $41.01 and a fifty-two week high of $83.98.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. During the same quarter in the prior year, the company posted $0.88 EPS. The company’s quarterly revenue was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts forecast that LivaNova PLC will post 3.73 EPS for the current year.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.